A phase I toxicity study of human rDNA interferon in patients with solid tumours.
AffiliationCancer Research Campaign Department of Medical Oncology, University of Manchester, Christie Hospital and Holt Radium Institute, Wilmslow Road, M20 9BX Manchester, England.
MetadataShow full item record
AbstractThis study was designed to evaluate the clinical tolerance to multiple IM injections of rDNA-produced human alpha-2 interferon (IFN) (Schering-Plough 30500) in patients with solid tumours. IFN was administered in escalating IM doses in separate groups of patients daily for 14 days and then twice weekly for a further 10 weeks. The dosage levels were 1, 3, 10, and 30 million U/injection. Subjective toxicity could be divided into two types, acute and chronic. The acute reactions took the form of an influenza-like syndrome consisting in chills, rigors, headache, tremor, nausea, vomiting, and myalgia. These symptoms were dose-related but tachyphylaxis developed with continued dosing. The chronic toxicity consisted of malaise, lethargy, fatigue, anorexia, and confusion. These symptoms were not so dose-dependent and tended to become more severe with prolonged treatment. Objective toxicity consisted of myelosuppression and liver dysfunction. Granulocyte counts below 1.0 X 10(9)/l were seen in three patients at the 30-million-U level, with platelet counts less than 100 X 10(9)/l in two of these. Elevation of the liver enzymes were seen in all five patients treated at 30 million U, but returned to normal after 1 week without IFN in all but one patient. A tolerable dose (IM) for phase II/III studies lies between 3 and 10 million U for daily scheduling and between 10 and 30 million U for twice-weekly injections.
CitationA phase I toxicity study of human rDNA interferon in patients with solid tumours. 1984, 13 (2):100-5 Cancer Chemother Pharmacol
JournalCancer Chemotherapy and Pharmacology
- A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
- Authors: Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M
- Issue date: 1999 Dec
- Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
- Authors: Ozer H, Gavigan M, O'Malley J, Thompson D, Dadey B, Nussbaum-Blumenson A, Snider C, Rudnick S, Ferraresi R, Norred S
- Issue date: 1983
- Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
- Authors: Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M
- Issue date: 2000 Sep
- Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients.
- Authors: Kurzrock R, Rosenblum MG, Quesada JR, Sherwin SA, Itri LM, Gutterman JU
- Issue date: 1986 Nov
- A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.
- Authors: Sriskandan K, Garner P, Watkinson J, Pettingale KW, Brinkley D, Calman FM, Tee DE
- Issue date: 1986